BioCryst’s Revenue Outlook Rises as Pharmacy Inventory Complicates ORLADEYO Sales Growth

BioCryst Pharmaceuticals raised its 2026 total revenue outlook after reporting higher third-quarter sales of ORLADEYO, its medicine for preventing hereditary angioedema attacks. The two developments have different drivers. The company left its ORLADEYO forecast unchanged; the increase in its overall revenue outlook came primarily from licensing income and orders for another medicine.

The quarter also included an initial inventory build by a new specialty pharmacy, making the sales figure a less direct measure of medicine dispensed to patients. Under the unchanged annual product forecast, implied fourth-quarter ORLADEYO revenue is below the third-quarter result. That arithmetic is useful context, although the company has not disclosed the size of the inventory contribution.

A growing medicine with a changing distribution channel

Hereditary angioedema (HAE) is a rare disease that causes recurrent episodes of swelling, including potentially dangerous swelling of the airway. ORLADEYO, or berotralstat, is taken once daily to prevent attacks by inhibiting plasma kallikrein, a protein involved in the pathway that causes swelling. It is a preventive medicine, not a treatment for an attack already underway.

In the United States, ORLADEYO is approved for patients aged two and older. BioCryst began launching oral pellets for children aged two to under 12 in August. An October FDA approval extended the pellet option to adults and adolescents who may prefer it to a capsule. That gives BioCryst another way to administer its existing medicine; the adult approval does not add a new age group to its U.S. indication.

The company also changed how the medicine reaches patients. In August, CareMed became its sole-source specialty pharmacy for ORLADEYO shipments to patients. In the third-quarter release, BioCryst said CareMed built an initial inventory and that this contributed to revenue growth. It expects the pharmacy’s inventory level to remain relatively stable over time.

Revenue recorded when a pharmacy stocks medicine and medicine subsequently dispensed to patients can occur in different periods. A stable inventory level would not require the same initial build in every quarter. BioCryst nevertheless said ORLADEYO revenue, excluding Europe, grew year over year even after removing that build. It did not quantify the build or the resulting growth rate in the release.

Reading the product sales comparison

BioCryst reported ORLADEYO revenue of $174.8 million in the third quarter, up from $159.1 million a year earlier. The comparison includes a portfolio change: BioCryst sold its European ORLADEYO business to Neopharmed Gentili on October 1, 2025. The year-earlier quarter included $13.8 million of revenue from that business.

Source: BioCryst third-quarter results. Growth is calculated from the disclosed amounts before rounding and includes the effect of CareMed’s initial inventory build.

Removing the former European business improves the period comparison, but it does not isolate end-patient demand. The reported 20.4% increase includes the unquantified pharmacy stocking effect. The company continues to receive certain revenue associated with the European arrangement, but the former direct business is no longer part of reported ORLADEYO sales in the same way.

BioCryst maintained its full-year ORLADEYO revenue forecast of $625 million to $645 million. With $481.4 million reported for the first nine months, the forecast implies approximately $143.6 million to $163.6 million in the fourth quarter. The $153.6 million midpoint is about 12.1% below the third-quarter figure of $174.8 million.

That does not establish that patient demand will fall by the same percentage. The forecast is a range, and the third-quarter figure includes the initial pharmacy build. Fourth-quarter shipments and commentary on dispensing will help investors distinguish the recurring sales pace from the transition effect.

Higher company guidance has other sources

BioCryst raised its full-year total revenue forecast to $715 million to $730 million from $690 million to $715 million. The company attributed the increase primarily to higher revenue associated with European licensing rights to navenibart and higher orders from international partners for RAPIVAB, an influenza medicine.

The licensing agreement granted a Neopharmed affiliate exclusive European commercialization rights to investigational navenibart. BioCryst received $70 million upfront and is eligible for up to $275 million in future regulatory and sales milestones, plus tiered royalties of 18% to 30% on applicable net sales. Milestones and royalties depend on future events; they are not equivalent to cash already received.

The distinction between cash and recognized revenue matters for the 2026 comparison. BioCryst reported $55.7 million of revenue from the agreement in the second quarter. Its June filing explains that the upfront payment was allocated between the delivered license and development services, with revenue for the latter recognized over time. The raised total-revenue forecast should therefore be read alongside the unchanged ORLADEYO forecast.

Profits and obligations sit side by side

Total third-quarter revenue was $180.3 million, compared with $159.4 million a year earlier. GAAP operating income increased to $53.3 million from $29.6 million, and GAAP net income rose to $37.9 million from $12.9 million. Operating margin expanded to 29.6% from 18.6%.

BioCryst reported non-GAAP operating income of $86.5 million, compared with $50.8 million. The $33.2 million adjustment to current-quarter GAAP operating income included stock-based compensation and costs related to the closure of the company’s Birmingham research facility and workforce reductions. Some closure costs require cash, while stock compensation is a noncash expense; the adjusted measure removes both from operating profit.

The nine-month GAAP net loss of $605.5 million needs separate context. It includes a $697.8 million noncash charge for acquired in-process research and development following BioCryst’s purchase of Astria Therapeutics. That charge reflects acquisition accounting, while the acquisition itself also involved a substantial cash payment and new borrowing.

In the first half, operating cash flow was $42.6 million and included the $70 million licensing upfront. Cash paid for Astria, net of cash acquired, was $489.5 million, partly financed by approximately $395 million in net term-loan proceeds. BioCryst also issued about 37.3 million shares in the transaction, equivalent to 14.6% of the 256.1 million shares outstanding at September 30. That percentage describes the issuance relative to the later share count, not the recipients’ current ownership.

At September 30, cash, cash equivalents and investments were $375.0 million, plus $1.5 million of restricted cash. The balance sheet also showed a $395.6 million secured term loan and a $421.7 million royalty financing obligation, both at carrying value. The loan is separate from the royalty obligation and was used in the Astria transaction.

BioCryst paid $33.7 million in cash on its royalty financing obligations during the third quarter. These arrangements direct a portion of ORLADEYO-related proceeds to financing counterparties, so the cash ultimately retained from sales is lower than the reported product revenue. The disclosed payment is a cash-flow item; it should not be added again to the royalty obligation’s balance-sheet carrying value.

Navenibart extends the development horizon

The January Astria acquisition brought BioCryst navenibart, an investigational injectable medicine intended to prevent HAE attacks. BioCryst says its pivotal ALPHA-ORBIT study is fully enrolled and expects top-line results covering six- and twelve-month endpoints in the third quarter of 2027.

The Phase 3 trial is randomized and placebo-controlled in adolescents and adults with type 1 or type 2 HAE. It is evaluating dosing every three or six months, with investigator-confirmed attack frequency during the six-month treatment period as a primary measure. Results will determine the strength of the evidence for those dosing schedules; the medicine has not been approved.

Patients already have preventive options. For example, the FDA’s review of DAWNZERA describes an injectable treatment studied at four- and eight-week intervals. Navenibart’s proposed longer intervals could offer a different treatment schedule, but its efficacy and safety cannot be ranked against existing medicines from separate placebo-controlled studies.

For BioCryst, the near-term indicators are ORLADEYO dispensing and fourth-quarter shipments after the pharmacy transition. Over a longer horizon, the 2027 navenibart results will determine whether the company can pursue another preventive option while continuing to fund development and meet its financing obligations.